Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

The UCLA Department of Medicine has announced that Priscilla Hsue, MD will be joining as the chief of the Division of Cardiology at UCLA, effective July 1, 2024. Hsue will come to UCLA from UC San Francisco (UCSF), where she leads a portfolio of clinical and translational studies on HIV-related cardiovascular disease and Long COVID.
News | Cardiovascular Education
UCLA Health Selects Dr. Priscilla Hsue as Cardiology Division Chief

March 21, 2024 — The UCLA Department of Medicine has announced that Priscilla Hsue, MD will be joining as the chief of ...

Home March 21, 2024
Home
In a new letter sent to federal officials on March 12, the American Medical Association (AMA) has presented six relief proposals to support physicians impacted by Change Healthcare hack, and praised the creation of the Change Healthcare/Optum Payment Disruption (CHOPD) Accelerated Payments.
News | Cybersecurity
AMA Presents Relief Proposals to Federal Officials to Support Physicians Impacted by Change Healthcare Hack

March 14, 2024 — The American Medical Association (AMA) has issued a new letter to federal officials in which it praised ...

Home March 14, 2024
Home
BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Centers for Medicare & Medicaid Services (CMS) approval for reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.
News | Heart Failure
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

March 13, 2024 —  BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
New Jersey-based Atlantic Health System’s Morristown Medical Center and New York-based NYU Langone Health, both nationally recognized cardiovascular programs, have announced that they are expanding their partnership to provide patients improved access to adult congenital heart disease services and the specialist directed care. Shown here, Trish O’Keefe, Senior Vice President, and President of Morristown Medical Center.
News | Cardiovascular Business
Atlantic Health System’s Morristown Medical Center and NYU Langone Health Expand Partnership to Include Adult Congenital Heart Disease

March 13, 2024 — Two nationally recognized cardiovascular programs, New Jersey-based Atlantic Health System’s Morristown ...

Home March 13, 2024
Home
Silence Therapeutics has announces positive topline 36-week data from its ongoing Phase 2 Study of Zerlasiran in patients with high Lipoprotein(a), reporting that the study met the primary endpoint and demonstrated highly significant reductions in Lp(a) to week 36.
News | Cardiovascular Clinical Studies
Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lp(a) Announced by Silence Therapeutics

March 13, 2024 — Silence Therapeutics has announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 ...

Home March 13, 2024
Home
Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, today announced that it has launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States
News | Structural Heart
New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform

March 12, 2024 — Medtronic plc, a global leader in healthcare technology, today announced two late-breaking data ...

Home March 12, 2024
Home
Getinge has announced the U.S. Food and Drug Administration’s (FDA) 510(k) clearance of the Vasoview Hemopro 3, the latest addition to the medtech company’s endoscopic vessel harvesting (EVH) solutions.
News | FDA
Getinge Announces US FDA 510(k) Clearance for Vasoview Hemopro 3 Endoscopic Vessel Harvesting (EVH) solution

March 12, 2024 — Getinge has announced the U.S. Food and Drug Administration’s (FDA) 510(k) clearance of the Vasoview ...

Home March 12, 2024
Home
The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling its HeartMate Touch System (version 1.0.32) for risk of unexpected pump stop or start. Issues may occur if the HeartMate Touch System is disconnected from a patient’s HeartMate Controller while a “pump stop” command is running. People who have the implantable HeartMate 3 Left Ventricular Assist Device may be affected.
News | FDA
FDA Announces Abbott Recall of HeartMate Touch Communication System for Unintentional Pump Start and Stop

March 12, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling its HeartMate Touch ...

Home March 12, 2024
Home
VahatiCor, Inc., a med tech company dedicated to helping patients with persistent ischemic heart disease, has announced the treatment of the first patient with the A-FLUX Reducer System, a treatment for patients with angina or chest pain.
News | Cardiovascular Business
VahatiCor, Inc. Announces Treatment of First Patient with the A-FLUX Reducer System Innovation for Patients Suffering from Angina Due to Persistent Ischemic Heart Disease

March 11, 2024 — VahatiCor, Inc., a med tech company dedicated to helping patients with persistent ischemic heart ...

Home March 11, 2024
Home
Georgia Tech-led effort to improve support device options for end-stage heart failure
News | Heart Failure
The Texas Heart Institute Collaborates on Multi-institutional DOD Grant to Develop Novel Left Ventricular Assist Device

March 8, 2024 —  The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, today announced that it has launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States
News | Stents
Silk Road Medical Expands TCAR Portfolio with Launch of Tapered ENROUTE Transcarotid Stent System

March 8, 2024 — Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact ...

Home March 08, 2024
Home
The approval is based on the results of SELECT, the largest cardiovascular outcomes trial ever completed for people with obesity and known heart disease
News | FDA
FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity

March 8, 2024 — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional ...

Home March 08, 2024
Home
CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction in non-fatal major adverse cardiac and cerebrovascular events
News | FDA
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

March 7, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 07, 2024
Home
An AMA letter sent to Secretary Bacerra outlines ongoing concerns of physicians amidst the cybersecurity incident that has impacted Change Healthcare
News | Cybersecurity
As Cyberattack Jeopardizes Physician Practices, AMA Demands Action

March 6, 2024 — As the cyber-takedown of Change Healthcare has forced medical practices to go without revenue for a ...

Home March 06, 2024
Home
Bodyport Inc., a biomarker-guided predictive care company, has presented data showing its FDA-cleared, non-invasive, biomarker-based technology for remote heart failure monitoring detected twice as many heart failure events as compared to the weight-based standard of care.
News | Cardiovascular Clinical Studies
Bodyport Presents Preliminary Analysis of SCALE-HF 1 Study on Remote Heart Failure Monitoring at Technology and Heart Failure Therapeutics (THT) Conference

March 6, 2024 — Bodyport Inc., a biomarker-guided predictive care company focused on heart failure, announced data from ...

Home March 06, 2024
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now